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Abstract: The outcome for glioblastoma patients remains extremely poor, despite the advances in surgical and medical fields. It is
hypothesized that glioblastoma progression, as well as tumor recurrence, is driven by a small number of cells called cancer stem cells
(CSCs), which are characterized by their ability of self-renewal and proliferation, giving rise to progeny of transformation into multiple
neuroepithelial lineages. Understanding the biology of CSCs is likely to explain why existing treatment strategies fail to affect the
relatively quiescent and resistant CSC compartment. Here, we review the current knowledge on CSCs in glial tumors. In addition, we
discuss the importance of the CSC hypothesis in the advancement of therapies for brain tumors.
Key words: Glioblastoma, cancer stem cell, therapy, resistance

1. Introduction
Glioblastoma is considered as the most aggressive
primary brain tumor and has an extremely poor prognosis.
The median 5-year survival rate is less than 3%, which
makes this disease a devastating condition for both patients
and their caregivers. Resistance to available therapies and
recurrence are common in most cases; identification and
molecular characterization of cancer stem cells (CSCs)
(Singh et al., 2003; Yuan et al., 2004) have shown that
these cells are responsible, in part, for resistance, as well as
tumor reformation.
In this review, we will try to summarize the recent
advances in glioblastoma biology, with a special focus
on glioblastoma CSCs (GSCs). We will also discuss the
molecular features of GSCs, and how these features can be
exploited as potential therapeutic strategies.
2. Glioblastoma
2.1. Background and epidemiology
Gliomas are the most common primary brain tumors
(approximately 80% of all cases). Glioblastoma in
particular is the most common and aggressive form of
glioma (Omuro and DeAngelis, 2013). Glioblastoma is
classified as WHO grade IV astrocytoma according to the
World Health Organization (WHO) classification of brain
tumors. The estimated incidence of brain and nervous
* Correspondence: zubeyde.erbayraktar@gmail.com
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system tumors is 240,000 cases per annum. According
to the Central Brain Tumor Registry of the United States
(CBTRUS) report in 2013, the incidence of glioblastoma is
3.19/100,000. and the median age at diagnosis is 64 years
(Ostrom et al., 2013; Thakkar et al., 2014).
The tumor is generally localized in the forebrain
(cerebrum). In most cases, tumor formation occurs
spontaneously.
However,
several
genetic
and
epidemiological risk factors have been identified, including
increased age, exposure to high-dose radiation, and history
of genetic disorders (e.g., Li–Fraumeni syndrome, Turcot’s
syndrome, retinoblastoma, and neurofibromatosis 1 and
2), allergies, ionizing radiation, and occupational exposure
to chemicals (e.g., pesticides, solvents) (Schwartzbaum et
al., 2006; Ostrom et al., 2014). In addition, while symptoms
vary between patients depending on tumor size and
localization, the common symptoms include increased
intracranial pressure, visual impairment, seizures, sensory
loss, mood/personality changes, and impaired cognitive
function (Wen and Kesari, 2008; Ostrom et al., 2014).
Magnetic resonance imaging (MRI) is performed in
suspected cases, and definitive diagnosis is made after
pathological examination of the biopsy specimen.
Glioblastoma patients have poor prognosis, and the
5-year survival rate after diagnosis is less than 5% (Ostrom
et al., 2013; Smoll et al., 2013). Long-term survival in
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glioblastoma is associated with several parameters,
including younger age, lower Ki-67, hypermethylation of
the O-6-methylguanine-DNA methyltransferase (MGMT)
promoter, and mutations in the IDH1 and IDH2 genes
(Scott et al., 1999; Krex et al., 2007; Yan et al., 2009;
Hartmann et al., 2010).
2.2. Molecular subtypes of glioblastoma
In 2010, Verhaak and colleagues integrated mRNA
expression profiles from different platforms and discovered
four distinct molecular subtypes (Verhaak et al., 2010). They
demonstrated that the so-called classical, mesenchymal,
proneural, and neural subtypes are characterized by
individual genetic signatures. The classical subtype is
characterized by chromosome 7 amplification (especially
EGFR gene amplification) paired with chromosome 10
loss, lack of TP53 mutations, focal 9p21.3 deletion (on
the CDKN2A locus), and high expression levels of NES,
Notch, and Sonic hedgehog (SHH) signaling pathway
elements (Verhaak et al., 2010). The mesenchymal subtype
is characterized by focal deletion of 17q11.2 (NF1 locus),
expression of previously described mesenchymal markers
(CHI3L1 and MET), and high levels of TNF and NF-κB
pathway elements (Verhaak et al., 2010). The proneural
subtype is characterized by mutations in the IDH1 and
PDGFRA genes, which are not commonly seen in other
subtypes (Verhaak et al., 2010). Integrated pathway analysis
of genomic alterations in glioblastoma has shown that the
PI(3)K/MAPK pathway, p53 pathway, and Rb pathway
are the most affected signaling pathways (Brennan et al.,
2013).
2.3. Standard of care
The current standard of care consists of gross total
resection (GTR), followed by radiotherapy and adjuvant
chemotherapy. GTR is the recommended approach as it
reduces intracranial pressure (Ricard et al., 2012), and the
extent of GTR has a significant effect on survival. Orringer
and colleagues reported that 1-year survival is significantly
higher in patients who undergo >90% resection (Orringer
et al., 2012).
Temozolomide (TMZ) is the current standard for
chemotherapy for glioblastoma. Stupp and colleagues
showed that TMZ administration during and after
radiotherapy significantly increases the median overall
survival and 2–5-year survival compared to radiotherapy
only (Stupp et al., 2009). Moreover, inactivation of MGMT
expression through promoter methylation is correlated
with higher sensitivity to TMZ (Esteller et al., 2000;
Hegi et al., 2005). Hegi and colleagues identified that
TMZ+radiotherapy leads to significantly higher median
overall survival in patients with methylated MGMT
promoter (21.7 months), compared to patients who received
radiotherapy only (15.3 months) (Hegi et al., 2005). Taken
together, these findings indicate the significant benefit

offered by TMZ treatment to glioblastoma patients with a
methylated MGMT promoter.
External beam radiation therapy (EBRT) is the current
standard in radiotherapy. Resistance to radiotherapy
is quite common, and it is known that a specific EGFR
variant (EGFRvIII) mediates radioresistance by inducing
the genes involved in double-stranded DNA repair
mechanisms (Mukherjee et al., 2009).
3. Glioblastoma stem cells
Different models have been proposed to explain the
complicated nature of tumor development. The CSC
hypothesis postulates a hierarchy in the tumor population,
where CSCs are positioned at the top. Thus, CSCs give rise
to different cell types through differentiation (Tang, 2012).
However, it should be noted that the relationship between
CSCs and differentiated tumor cells is bidirectional; in
vitro and in vivo interventions (treatment modalities,
silencing/overexpressing genes and/or proteins, hypoxia)
may trigger dedifferentiation of tumor cells to GSCs,
thus creating a dynamic equilibrium between these cell
populations (Tang, 2012).
3.1. Molecular features of GSCs
Long-term clonal repopulation and self-renewal represent
two key features of CSCs (Nguyen et al., 2012). CSCs
cannot be easily distinguished from differentiated tumor
cells in the case of tumors that display low levels of
hierarchy, and in relatively homogeneous tumors (Nguyen
et al., 2012; Kreso et al., 2014).
GSCs share several features with neural stem cells
(NSCs), including expression of Nestin and CD133, and
can form spheres in the presence of required growth
factors (Zhu et al., 2014). Similar to NSCs, GSCs also
rely on certain transcription factors, which are crucial for
their maintenance. These factors include sex-determining
region Y-box 2 (SOX2), octamer-binding transcription
factor (OCT4), and Nanog homeobox (NANOG) (Schmitz
et al., 2007; Ikushima et al., 2011). A list of key biological
markers that are used for characterization of GSCs is
provided in the Table.
CD133 has served as one of the most frequently used
markers to characterize GSCs. CD133+ glioblastoma cells
are able to form tumors, even in low cell numbers. Singh
and colleagues reported that 100 CD133+ cells are able to
form tumors when transplanted into the brains of severe
combined immunodeficient (SCID) mice; on the other
hand, injection of high numbers of CD133– cells (105) does
not cause tumor formation (Singh et al., 2004).
Contrary to this notion, different studies have shown
the presence of CD133– GSCs (Beier et al., 2007, 2011).
Comprehensive gene expression studies on molecular
subtypes of glioblastoma have shown that CD133 positivity
is enhanced in the mesenchymal subtype (Phillips et al.,
2006).
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Table . Important markers for characterization of GSCs.
Marker

Function

Reference

CD133

Positive association with aggressiveness

Brescia et al. (2013)

CD44

Positive association with aggressiveness

Pietras et al. (2014)

CD15

Enrichment marker in CD133– tumors

Kahlert et al. (2012), Auffinger et al. (2014)

TLX

Self-renewal

Zou et al. (2012)

ID1

Self-renewal

Soroceanu et al. (2013)

Integrin α6

Regulation of self-renewal, proliferation, and tumor formation

Lathia et al. (2010)

L1CAM

Maintenance of growth and survival of CD133+ cells

Bao et al. (2008)

Nestin

Regulation of sphere formation, tumor growth, invasion

Matsuda et al. (2015)

SOX2

Maintenance of self-renewal

Seymour et al. (2015)

Osteopontin

Maintenance of stemness, sphere formation, tumor growth

Lamour et al. (2015)

SOX2 is a transcription factor that has a critical role in
maintenance of self-renewal of stem cells, and especially
neural stem cells (Ellis et al., 2004; Thiel, 2013). SOX2
overexpression at mRNA and protein levels has been
identified in tumor tissues (Alonso et al., 2011; Annovazzi
et al., 2011). Gene amplification (Brennan et al., 2013),
as well as hypomethylation of the SOX2 promoter
(Alonso et al., 2011), can explain SOX2 overexpression
in glioblastoma. GSCs express SOX2, which maintains
stemness through the TGF-β signaling pathway (Ikushima
et al., 2009). Gangemi and colleagues showed that
loss of SOX2 expression impairs cell proliferation and
tumorigenicity of glioblastoma cells in vivo (Gangemi
et al., 2009). Given the limited expression of SOX2 in
the adult brain (Baer et al., 2007; Seymour et al., 2015),
targeting SOX2 can be a potential strategy for treatment
of glioblastoma.
Previously, Chen and colleagues showed that ablation
of Nestin-expressing glioblastoma cells leads to increased
survival of tumor-bearing mice (Chen et al., 2012). This
finding highlights the importance of Nestin with respect
to tumor propagation.
TLX is a nuclear receptor that is specifically expressed
in adult NSCs, and its presence is required for neurogenesis
in the subventricular zone (SVZ) (Liu et al., 2008). In
addition, mouse models of glioblastoma have shown
that the combination of forced TLX overexpression and
loss of tumor suppressor genes (TP53 and INK4A/ARF)
is sufficient to cause tumor formation (Liu et al., 2010;
Park et al., 2010; Zou et al., 2012). Liu and colleagues
identified that TLX overexpression leads to migration of
progenitor and/or stem cells from their natural niche, and
combination of p53 mutations and TLX overexpression
lead to glioblastoma initiation in vivo (Liu et al., 2010).
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While Tlx has been shown to be druggable (Benod et
al., 2014), identification and characterization of potent
Tlx inhibitors warrant further studies. However, given
the close link between TLX and histone deacetylases
(HDACs), HDAC inhibitors can be used to target TLX+
GSCs (Xie et al., 2014).
L1CAM is a neural adhesion molecule that regulates
different cellular processes, including migration, invasion,
adhesion, survival, and growth (Maness and Schachner,
2007). Bao and colleagues showed that L1CAM is
differentially overexpressed in CD133+ glioblastoma
cells (Bao et al., 2008). Cheng and colleagues provided
supporting evidence for this phenomenon, showing that
L1CAM is differentially overexpressed in the invasive
fronts of glioblastoma (Cheng et al., 2011). In another
study, Held-Feindt and colleagues showed that TGF- β1
signaling regulates L1CAM expression in glioblastoma,
and L1CAM confers resistance to TMZ (Held-Feindt
et al., 2012). L1CAM also participates in regulation of
DNA damage checkpoint response. Cheng and colleagues
showed that the intracellular domain of L1CAM is cleaved
from the membrane-bound form through ADAM10- (A
Disintegrin and Metalloprotease 10) and Presinilinmediated cleavage. This, in turn, leads to its translocation
to the nucleus, where it induces NBS1 expression
through c-Myc (Cheng et al., 2011). As a result, L1CAM
enhances DNA damage checkpoint activation and confers
radioresistance to GSCs.
Osteopontin is a secreted phosphoprotein that is
critical for osteoblast function (Jan et al., 2010). In
addition to its role in bone formation, osteopontin is
an important angiogenic molecule for glioblastoma,
as it is found in the tumor microvasculature (Takano
et al., 2000). Osteopontin also functions as a driver of
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invasion and tumor growth. Jan and colleagues showed
that osteopontin enhances invasion of glioblastoma cells
by inducing MMP-2 secretion and vimentin expression
(Jan et al., 2010). They also demonstrated that 5-aza-2’deoxycytidine, an anticancer agent, reduces cell invasion
and inhibits glioblastoma tumor growth by suppressing
osteopontin expression (Jan et al., 2010).
Inhibitor of DNA binding/differentiation (Id)
proteins are negative regulators of the basic HLH family
of transcription factors (Perk et al., 2005). Id proteins are
well known for their functions related to differentiation,
as well as self-renewal of stem cells (O’Brien et al., 2012;
Romero-Lanman et al., 2012; Lasorella et al., 2014). Id1
overexpression is a common feature of different cancers
(Perk et al., 2006; Lasorella et al., 2014) and is also related to
metastasis of breast cancer to the lungs (Gupta et al., 2007).
Id1 overexpression has been documented in glioblastoma,
which is also positively correlated with tumor grade and
proliferation index (Vandeputte et al., 2002). Given the link
between TGF-β and Id1 expression, inhibition of TGF-β
signaling can be a potential strategy for glioblastoma
treatment. Indeed, Anido and colleagues found that
inhibition of the TGF-β signaling pathway decreases the
number of CD44high/Id1high GSCs through suppression of
Id1 and Id3 expression (Anido et al., 2010). They concluded
that this strategy can be employed to overcome tumor
recurrence, which is driven through GSCs.
3.2. Deregulated signaling pathways in GSCs
Deregulation of cellular signaling pathways is one of
the major features that distinguishes CSCs from NSCs.
Previous studies have shown that several key signaling
pathways are deregulated in glioblastoma. These include
Notch signaling, Wnt/beta-catenin signaling, receptor
tyrosine kinase (RTK) signaling. and Sonic hedgehog
(SHH) signaling.
RTK signaling pathways have been extensively studied
in glioblastoma. Of note, comprehensive genetic analyses
have shown that EGFR gene amplification and activating
mutations, as well as PDGFR amplification, are common
events in glioblastoma (Verhaak et al., 2010). Activation of
RTK signaling pathways leads to constitutive activation of
the downstream PI3K/Akt signaling, which is responsible
for maintenance of cell growth and proliferation.
Notch signaling is critical for stem cells, as it functions
in regulation of self-renewal and differentiation. Tchorz
and colleagues showed that constitutive activation of
Notch signaling leads to tumor formation and astroglial
lineage entry (Tchorz et al., 2012).
SHH signaling is a key pathway for maintenance of
self-renewal and regulates proliferation of GSCs (Clement
et al., 2007; Xu et al., 2008; Takezaki et al., 2011). In
addition, hyperactivation of SHH signaling and PTEN
coexpression are associated with reduced survival (Xu et

al., 2008). Bar and colleagues showed that cyclopaminemediated inhibition of SHH signaling depletes GSCs (Bar
et al., 2007). Their findings suggest that SHH inhibition
can be a potential strategy to specifically target GSCs.
CSCs also rely on Wnt/beta-catenin signaling to
regulate stemness and differentiation. In addition, Kim and
colleagues reported that activation of Wnt/beta-catenin
signaling can contribute to radioresistance in GSCs (Kim
et al., 2012). Thus, targeting Wnt/beta-catenin signaling
may serve as an alternative therapeutic strategy. Recently,
De Robertis and colleagues identified and characterized a
small molecule inhibitor (SEN461) of the canonical Wnt/
beta-catenin signaling pathway. They found that in vivo
administration of SEN461 reduces tumor growth (De
Robertis et al., 2013).
4. Glioblastoma stem cells: a therapeutic challenge
It is hypothesized that treatment failure results from
insufficient drug delivery and the targeting of differentiated
tumor cells rather than CSCs (Beier et al., 2011). CSCs use
different mechanisms to escape chemotherapy-induced
cell death, including activation of DNA damage response
(Bao et al., 2006) and functions of specific proteins
including MGMT and multidrug resistance proteins (e.g.,
ABCB1) (Beier et al., 2011).
Another factor affecting chemoresistance is tumor
evolution. It has been suggested that tumors adapt a
chemoresistant phenotype through selection of preexisting
clones or formation of de novo subclones (Prados et al.,
2015). Supporting evidence for this notion has come from
a recent study, where Johnson and colleagues analyzed
the origin and evolution of recurrent glioma (Johnson
et al., 2014). Through exome sequencing, they identified
that TMZ treatment causes a significant portion of the
recurrent tumors to follow an alternative path to highgrade glioma. Moreover, they found that recurrent tumors
have a TMZ-induced mutagenesis signature (in RB and
Akt-mTOR genes) (Johnson et al., 2014).
In another study, Auffinger and colleagues
demonstrated for the first time that glioblastoma cells are
capable of interconverting between non-CSCs and CSCs
upon chemotherapy (Auffinger et al., 2014). They showed
that TMZ treatment increases the proportion of GSCs
in vitro and in vivo. In addition, lineage-tracing analysis
showed that this increase is not a result of enhanced cell
proliferation, but rather a result of a phenotypic shift to
the CSC state (as demonstrated by stem cell markers,
including CD133, SOX2, Oct4, and Nestin). Overall, their
results suggest a potential mechanism for escape from
chemotherapy.
Targeting self-renewal capacity of GSCs has been used
as a promising strategy for treatment of glioblastoma.
Recently, Hale and colleagues showed that GSCs are
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enriched in CD36 (a scavenger receptor), which can
be used to distinguish self-renewing cells. In addition,
they found that reduction of CD36 expression leads to
loss of self-renewal, tumor initiation capacity, and loss
of integrin alpha 6 expression. Overall, they concluded
that glioblastoma CSCs selectively use CD36 for their
maintenance (Hale et al., 2014).
Deregulated miRNA expression (i.e. downregulation
of tumor-suppressor miRNAs) can also contribute to
tumor formation and/or progression in glioblastoma.
Gal and colleagues compared miRNA expression profiles
of CD133+ and CD133– glioblastoma CDCs and found
that several miRNAs (including miR-451, miR-486, and
miR-425) are overexpressed in CD133– glioblastoma
CDCs compared to CD133+ cells. They also showed
that exogenous overexpression of miR-451 disperses
neurosphere formation and inhibits cell proliferation
(Gal et al., 2008). Their results indicate that restoring
expression of tumor-suppressive miRNAs can be used as
an alternative strategy for treatment of glioblastoma.
Hitomi and colleagues reported that connexins, which
are structural elements of gap junctions, show differential
expression between GSCs and differentiated tumor cells
(Hitomi et al., 2015). Their results show that differentiated
tumor cells predominantly express connexin 43 (Cx43),
whereas GSCs express Cx46. In addition, they found that

Cx46 expression decreases and Cx43 expression increases
during differentiation of GSCs. Reduced expression of
Cx46 impaired the tumor-forming capacity and selfrenewal of glioblastoma CSCs.
Gamma-secretase inhibitors and RNA interference
have been previously used to inhibit Notch signaling,
which leads to reduced radioresistance and impaired
formation of tumor spheres (Fan et al., 2010; Wang et al.,
2010).
5. Concluding remarks
The advances in stem cell biology in the past decade have
helped us to better understand the development and
pathogenesis of brain tumors. Despite the identification
and characterization of GSCs, the existence of a specific
cell population and their specific roles in the context of
tumor development are still debated. By utilizing the key
molecular features of CSCs, new therapeutic strategies can
be developed to achieve more durable clinical responses.
Alternatively, given the inherent tumor tropism of NSCs,
endogenous and/or engineered NSCs can be used as
therapeutic delivery vehicles for treatment of glioblastoma.
Taken together, translating the accumulated knowledge on
the biology of NSCs and CSCs with well-designed studies
may bring new possibilities for effective therapies to
glioblastoma patients.
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